MCID: HRP006
MIFTS: 65

Herpes Simplex

Categories: Fetal diseases, Infectious diseases, Oral diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Herpes Simplex

MalaCards integrated aliases for Herpes Simplex:

Name: Herpes Simplex 12 54 42 43 15
Herpesvirus Hominis Disease 12
Herpes Simplex Infections 71
Herpes Simplex Disease 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8566
ICD9CM 34 054
MeSH 43 D006561
SNOMED-CT 67 88594005
ICD10 32 B00 B00.9
UMLS 71 C0019348

Summaries for Herpes Simplex

MedlinePlus : 42 Herpes is an infection that is caused by a herpes simplex virus (HSV). Oral herpes causes cold sores around the mouth or face. Genital herpes affects the genitals, buttocks or anal area. Genital herpes is a sexually transmitted disease (STD). It affects the genitals, buttocks or anal area. Other herpes infections can affect the eyes, skin, or other parts of the body. The virus can be dangerous in newborn babies or in people with weak immune systems. There are two types of HSV: HSV type 1 most commonly causes cold sores. It can also cause genital herpes. HSV type 2 is the usual cause of genital herpes, but it also can infect the mouth. HSV spreads through direct contact. Some people have no symptoms. Others get sores near the area where the virus has entered the body. They turn into blisters, become itchy and painful, and then heal. Most people have outbreaks several times a year. Over time, you get them less often. Medicines to help your body fight the virus can help lessen symptoms and decrease outbreaks.

MalaCards based summary : Herpes Simplex, also known as herpesvirus hominis disease, is related to herpes simplex encephalitis and genital herpes, and has symptoms including fever, pruritus and halitosis. An important gene associated with Herpes Simplex is NECTIN1 (Nectin Cell Adhesion Molecule 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include mouth, face and genitalia, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A viral infectious disease that results in formation of lesions, located in mouth, located in face, located in genitalia, or located in hands, has material basis in Human herpesvirus 1 or has material basis in Human herpesvirus 2, which are transmitted by direct contact with an active lesion or body fluid of an infected person.

Wikipedia : 74 Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known by their taxonomical names Human... more...

Related Diseases for Herpes Simplex

Diseases in the Herpes Simplex family:

Congenital Herpes Simplex

Diseases related to Herpes Simplex via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1203)
# Related Disease Score Top Affiliating Genes
1 herpes simplex encephalitis 35.1 UNC93B1 TRAF3 TLR3 TICAM1 TBK1 IRF3
2 genital herpes 34.4 TNFRSF14 NECTIN1 IFI16
3 herpetic whitlow 33.5 TNFRSF14 NECTIN1
4 acute retinal necrosis syndrome 33.2 TNFRSF14 NECTIN1
5 encephalitis 32.7 UNC93B1 TRAF3 TLR3 TICAM1 IRF3 DDX58
6 measles 31.6 TLR3 IRF3 EIF2AK2 DDX58
7 viral infectious disease 31.4 TLR3 TBK1 IRF3 EIF2AK2 DDX58
8 hepatitis 31.2 TICAM1 TBK1 IRF3 EIF2AK2 DDX58
9 kaposi sarcoma 31.2 TLR3 TBK1 IRF3 IFI16
10 newcastle disease 31.1 TLR3 IRF3 EIF2AK2 DDX58
11 rabies 31.0 TLR3 PML IRF3 DDX58
12 hepatitis c 30.7 TLR3 TBK1 IRF3 EIF2AK2 DDX58
13 west nile virus 30.4 TLR3 IRF3 DDX58
14 influenza 30.4 TRAF3 TLR3 PML IRF3 EIF2AK2 DDX58
15 herpes simplex virus keratitis 12.8
16 congenital herpes simplex 12.8
17 eczema herpeticum 12.6
18 herpes simplex virus stromal keratitis 12.5
19 encephalopathy, acute, infection-induced 2 12.5
20 encephalopathy, acute, infection-induced 1 12.5
21 encephalopathy, acute, infection-induced 8 12.3
22 encephalopathy, acute, infection-induced 5 12.1
23 encephalopathy, acute, infection-induced 7 12.1
24 encephalopathy, acute, infection-induced 6 12.1
25 neonatal herpes 12.0
26 erythema multiforme 11.9
27 mollaret meningitis 11.8
28 cytomegalovirus infection 11.7
29 proctitis 11.7
30 aphthous stomatitis 11.7
31 viral pneumonia 11.7
32 cytomegalic inclusion disease 11.7
33 immunodeficiency 31a 11.6
34 herpetic gastritis 11.6
35 hyper-ige recurrent infection syndrome 2, autosomal recessive 11.3
36 hydrocephalus, endocardial fibroelastosis, and cataracts 11.3
37 caspase 8 deficiency 11.3
38 immunodeficiency 62 11.3
39 salivary gland disease 11.3
40 pseudomembranous conjunctivitis 11.3
41 congenital intrauterine infection-like syndrome 11.3
42 pudendal neuralgia 11.3
43 recessive dystrophic epidermolysis bullosa-generalized other 11.3
44 torch syndrome 11.3
45 neurological consequences of cytomegalovirus infection 11.3
46 keratitis, hereditary 11.3
47 chickenpox 11.1
48 vaccinia 10.9
49 meningitis 10.9
50 viral encephalitis 10.8

Graphical network of the top 20 diseases related to Herpes Simplex:



Diseases related to Herpes Simplex

Symptoms & Phenotypes for Herpes Simplex

UMLS symptoms related to Herpes Simplex:


fever, pruritus, halitosis, snoring, pelvic pain

GenomeRNAi Phenotypes related to Herpes Simplex according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.36 EIF2AK2 TBK1
2 Decreased viability GR00221-A-2 10.36 EIF2AK2 TBK1
3 Decreased viability GR00221-A-3 10.36 EIF2AK2
4 Decreased viability GR00221-A-4 10.36 EIF2AK2
5 Decreased viability GR00301-A 10.36 EIF2AK2 TBK1
6 Decreased viability GR00342-S-1 10.36 EIF2AK2 TBK1 TLR3
7 Decreased viability GR00342-S-2 10.36 EIF2AK2 TBK1 TLR3
8 Decreased viability GR00402-S-2 10.36 EIF2AK2 TBK1 TLR3 CREB3 DDX58 HCFC1
9 no effect GR00402-S-1 9.62 CREB3 DDX58 EIF2AK2 HCFC1 HCFC2 IFI16

MGI Mouse Phenotypes related to Herpes Simplex:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 DDX58 EIF2AK2 IRF3 PILRA PML POU2F1
2 homeostasis/metabolism MP:0005376 10.13 CREB3 DDX58 HCFC2 IRF3 NECTIN1 PILRA
3 immune system MP:0005387 10.1 DDX58 EIF2AK2 HCFC2 IRF3 PILRA PML
4 mortality/aging MP:0010768 9.86 CREB3 DDX58 EIF2AK2 HCFC1 HCFC2 NECTIN1
5 liver/biliary system MP:0005370 9.76 DDX58 HCFC1 PILRA POU2F1 TBK1 TICAM1
6 neoplasm MP:0002006 9.1 DDX58 EIF2AK2 PML TAP1 TICAM1 TLR3

Drugs & Therapeutics for Herpes Simplex

Drugs for Herpes Simplex (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Bisoprolol Approved Phase 4 66722-44-9 2405
5
Acyclovir Approved Phase 4 59277-89-3 2022
6
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
12
Difluprednate Approved Phase 4 23674-86-4 443936
13
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
14 Anti-Inflammatory Agents Phase 4
15 Hydrocortisone hemisuccinate Phase 4
16 Hydrocortisone 17-butyrate 21-propionate Phase 4
17 Autonomic Agents Phase 4
18 Antiparasitic Agents Phase 4
19 Antiprotozoal Agents Phase 4
20 Denatonium Phase 4
21 Neurotransmitter Agents Phase 4
22 Antihypertensive Agents Phase 4
23 Hydrocortisone-17-butyrate Phase 4
24 Adrenergic beta-1 Receptor Antagonists Phase 4
25 Adrenergic Antagonists Phase 4
26 Adrenergic beta-Antagonists Phase 4
27 Sympatholytics Phase 4
28 Adrenergic Agents Phase 4
29 Ganciclovir triphosphate Phase 4
30 valacyclovir Phase 4
31 Protective Agents Phase 4
32 Methylprednisolone Acetate Phase 4
33 Neuroprotective Agents Phase 4
34 Ophthalmic Solutions Phase 4
35
mometasone furoate Approved, Investigational, Vet_approved Phase 3 83919-23-7
36
Zinc Approved, Investigational Phase 3 7440-66-6 32051
37
Famciclovir Approved, Investigational Phase 3 104227-87-4 3324
38
Halofantrine Approved Phase 3 69756-53-2 37393
39
Aluminum sulfate Approved Phase 3 10043-01-3
40
Vidarabine Approved, Investigational Phase 3 24356-66-9 32326 21704
41
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
42
Penciclovir Approved Phase 3 39809-25-1 4725
43
Sodium citrate Approved, Investigational Phase 3 68-04-2
44
Melphalan Approved Phase 3 148-82-3 4053 460612
45
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
46
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
47 Dermatologic Agents Phase 3
48 Anti-Allergic Agents Phase 3
49 Monophosphoryl lipid A Phase 3
50 polysaccharide-K Phase 3

Interventional clinical trials:

(show top 50) (show all 288)
# Name Status NCT ID Phase Drugs
1 The Safety, Efficacy and Convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%. Unknown status NCT00467662 Phase 4 Acyclovir 5%;Docosanol 10%
2 Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children Completed NCT01682109 Phase 4 Valacyclovir
3 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
4 Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia Completed NCT01794897 Phase 4 Experimental: Valacyclovir treatment;Placebo comparator
5 Effect of Tenofovir on Genital HSV Shedding: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01448616 Phase 4 TDF;Placebo Vaginal Gel;Vaginal TFV Gel;Placebo Tablets
6 A Randomized, Double-Blind, Placebo Controlled Crossover Trial Using Valacyclovir to Suppress HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Persons Completed NCT00161434 Phase 4 valacyclovir;placebo
7 An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Completed NCT00158860 Phase 4 Valaciclovir;Placebo
8 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of Acyclovir on Rapidly Cleared Herpes Simplex Virus Type 2 Genital Reactivation Episodes in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00723229 Phase 4 acyclovir
9 A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons Completed NCT00527618 Phase 4 valacyclovir;acyclovir
10 A Randomized Controlled Crossover Trial of Acylcovir Among HIV and HSV-2 Co-Infected Women, Chiang Rai, Thailand Completed NCT00362596 Phase 4 acyclovir
11 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Acyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT00362297 Phase 4 acyclovir;valacyclovir
12 A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults Completed NCT01346475 Phase 4 valacyclovir;Valacyclovir
13 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
14 A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
15 Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial Active, not recruiting NCT02152358 Phase 4 Aciclovir;Ganciclovir;Placebo
16 A Randomized Trial of Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis Not yet recruiting NCT03626376 Phase 4 oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily;oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
17 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Orofacial Herpes Infections. Not yet recruiting NCT04065971 Phase 4 2LHERP®;Placebo
18 Low Dose Versus High Dose Steroids in Treatment of Viral Encephalitis Not yet recruiting NCT04103684 Phase 4 Methylprednisolone;Dexamethasone
19 Comparison Between the Sensibility of the Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis Terminated NCT02045082 Phase 4
20 A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections Unknown status NCT03178747 Phase 3
21 Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System Unknown status NCT00006132 Phase 3 acyclovir
22 Herpetic Eye Disease Study (HEDS) I Unknown status NCT00000138 Phase 3 Prednisolone Phosphate;Acyclovir
23 An International, Randomized, Double-Blind, Placebo-Controlled Study of Valacyclovir for the Suppression of Recurrent Ano-Genital HSV Infections in HIV-Infected Subjects Unknown status NCT00005663 Phase 3 Valacyclovir hydrochloride
24 MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS. Unknown status NCT01702103 Phase 3 Mometasone furoate
25 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
26 A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes) Completed NCT00001038 Phase 3 Valacyclovir hydrochloride;Acyclovir
27 Open-label Study of ASP2151 in Herpes Simplex Patients Completed NCT02209324 Phase 3 ASP2151
28 Study to Evaluate the Safety of GSK Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL in HSV Seropositive or Seronegative Subjects Without Genital Herpes Disease Completed NCT00698568 Phase 3
29 A Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (gD2‑AS04) in Healthy HSV Seronegative and Seropositive Female Subjects Aged 10-17 Years. Completed NCT00224484 Phase 3
30 Safety of SmithKline Beecham Biologicals' Herpes Simplex Candidate Vaccine (gD2t) With MPL & Its Efficacy to Prevent Genital Herpes Disease in HSV Positive or Negative Consorts of Subjects With Genital Herpes Disease Completed NCT00699764 Phase 3
31 Phase III Study of ASP2151 in Herpes Simplex Patients ― A Double-blind, Placebo-controlled Study ― Completed NCT01959295 Phase 3 ASP2151;ASP2151 placebo
32 Low Dose Versus Weight-based Intravenous Acyclovir for Herpes Simplex Virus Prophylaxis in the Neutropenic Patient Completed NCT00855309 Phase 3 acyclovir sodium
33 A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herpes Simplex Infection Completed NCT00098059 Phase 3 Famciclovir
34 Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine Completed NCT00000985 Phase 3 Vidarabine;Acyclovir;Foscarnet sodium
35 A Phase III, Double-blind, Randomized, Study to Compare: 1) the Immunogenicity and Safety of 3 Commercial Scale Consistency Lots of GlaxoSmithKline (GSK) Biologicals' Herpes Simplex Candidate Vaccine in Healthy HSV-1 and -2 Seronegative (HSV 1-/2-) Female Subjects Aged 10 - 17 Years, and 2) Vaccine Immunogenicity in Healthy HSV 1-/2- Females Aged 10 - 17 Years With Healthy HSV 1-/2- Adult Females Completed NCT00224471 Phase 3
36 Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Limited to Skin, Eyes, and Mouth Completed NCT00006135 Phase 3 acyclovir
37 A Multicenter, Open-label Study to Evaluate Preventive Efficacy for Herpes Simplex Virus Infection and Safety of 256U87 (Valaciclovir Hydrochloride) in Adult and Pediatric Hematopoietic Stem Cell Transplantation Patients Completed NCT01602562 Phase 3 VACV tablets (Adults or pediatrics) or granules (pediatrics)
38 An Open Label, Multi-Centre, Phase III, Subject Initiated Safety Study of ME-609 in Treatment of Recurrent Herpes Simplex Labialis in Adolescents Completed NCT00375570 Phase 3 ME-609
39 Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis Completed NCT02265913 Phase 3 Acyclovir 5 percent (Perrigo);Acyclovir 5 percent (Reference);Placebo cream
40 Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth Completed NCT00004757 Phase 3 acyclovir
41 VALacyclovir In Delaying Antiretroviral Treatment Entry Completed NCT00860977 Phase 3 valacyclovir;Placebo
42 A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes Completed NCT01281007 Phase 3 Famciclovir;Aciclovir
43 A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initiated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis Completed NCT00361881 Phase 3 ME-609;acyclovir in ME-609 vehicle;Vehicle
44 A Randomized, Double-Blind, to Compare Non-inferiority Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis. Completed NCT01257074 Phase 3 Acyclovir 50mg/g;Penciclovir 10mg/g
45 A Randomized, Double-blind, Placebo-controlled, Multi-Center Trial of Zinc for the Treatment of Herpes Simplex Labialis (HSL) Completed NCT00809809 Phase 3 Zicam (Ionic zinc);placebo
46 A Phase III Double-Blind, Placebo-Controlled Trial of Long Term Therapy of Herpes Simplex Encephalitis (HSE): An Evaluation of Valacyclovir (CASG-204) Completed NCT00031486 Phase 3 Valacyclovir;Placebo
47 A Placebo-Controlled Phase III Evaluation of Suppressive Therapy With Oral Acyclovir Suspension Following Neonatal Herpes Simplex Virus Infections Limited to the Skin, Eye, and Mouth Completed NCT00031447 Phase 3 Acyclovir;Placebo
48 A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis Completed NCT00878072 Phase 2, Phase 3 Famciclovir
49 A Randomized, Double-Blind, Active-Controlled, Subject Initiated Study Comparing ME-609 to Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis in Immunocompromised Patients Completed NCT00735761 Phase 3 ME-609;Acyclovir in ME-609 vehicle (5% acyclovir)
50 A Randomized, Double-Blind, Placebo-Controlled Evaluation of Valaciclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples Completed NCT00001649 Phase 3 Valaciclovir

Search NIH Clinical Center for Herpes Simplex

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acyclovir
Acyclovir Sodium
Benzocaine
BENZOCAINE PWDR
famciclovir
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Herpes Simplex Virus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Methylene blue
valacyclovir
Valacyclovir hydrochloride

Cochrane evidence based reviews: herpes simplex

Genetic Tests for Herpes Simplex

Anatomical Context for Herpes Simplex

The Foundational Model of Anatomy Ontology organs/tissues related to Herpes Simplex:

19
Mouth, Face, Genitalia, Hands

MalaCards organs/tissues related to Herpes Simplex:

40
T Cells, Brain, Testes, Skin, Eye, Liver, Endothelial

Publications for Herpes Simplex

Articles related to Herpes Simplex:

(show top 50) (show all 30267)
# Title Authors PMID Year
1
Can endoscopists differentiate cytomegalovirus esophagitis from herpes simplex virus esophagitis based on gross endoscopic findings? 61 42
31169688 2019
2
Essential Oils for the Treatment of Herpes Simplex Virus Infections. 61 42
31234166 2019
3
Herpesviruses, autoimmunity and epilepsy: Peptide sharing and potential cross-reactivity with human synaptic proteins. 42
31404705 2019
4
A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics. 54 61
20375153 2010
5
Bimolecular complementation defines functional regions of Herpes simplex virus gB that are involved with gH/gL as a necessary step leading to cell fusion. 54 61
20130048 2010
6
Glycoprotein D actively induces rapid internalization of two nectin-1 isoforms during herpes simplex virus entry. 54 61
20089288 2010
7
Herpes simplex virus tegument ICP0 is capsid associated, and its E3 ubiquitin ligase domain is important for incorporation into virions. 54 61
19906912 2010
8
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. 54 61
19521665 2009
9
Fusion between perinuclear virions and the outer nuclear membrane requires the fusogenic activity of herpes simplex virus gB. 54 61
19759132 2009
10
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. 54 61
19702506 2009
11
[Expression of blood Toll-like receptors and cytokines in children with recurrent herpes simplex]. 54 61
19755019 2009
12
Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. 54 61
19386594 2009
13
Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. 54 61
19279115 2009
14
Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. 54 61
19129446 2009
15
Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy. 54 61
19213040 2009
16
A 10-year molecular survey of herpes simplex virus type 1 in Germany demonstrates a stable and high prevalence of genotypes A and B. 54 61
19186100 2009
17
Delivery of Interferon-gamma by an adenovirus vector blocks herpes simplex virus Type 1 reactivation in vitro and in vivo independent of RNase L and double-stranded RNA-dependent protein kinase pathways. 54 61
19042034 2009
18
Therapeutic efficacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. 54 61
18728637 2008
19
Herpes simplex virus type 1 Us3 gene deletion influences toll-like receptor responses in cultured monocytic cells. 54 61
19025601 2008
20
Role for nectin-1 in herpes simplex virus 1 entry and spread in human retinal pigment epithelial cells. 54 61
18803666 2008
21
Involvement of HVEM receptor in activation of nuclear factor kappaB by herpes simplex virus 1 glycoprotein D. 54 61
18671825 2008
22
Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1. 54 61
18653740 2008
23
Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. 54 61
18573279 2008
24
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. 54 61
18667508 2008
25
HVEM and nectin-1 are the major mediators of herpes simplex virus 1 (HSV-1) entry into human conjunctival epithelium. 54 61
18502984 2008
26
STAT-1- and IRF-3-dependent pathways are not essential for repression of ICP0-null mutant herpes simplex virus type 1 in human fibroblasts. 54 61
18579584 2008
27
Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. 54 61
18667634 2008
28
Effect of conjugation with polypeptide carrier on the enzymatic degradation of Herpes simplex virus glycoprotein D derived epitope peptide. 54 61
18651758 2008
29
Herpes simplex virus type 1 ICP27 regulates expression of a variant, secreted form of glycoprotein C by an intron retention mechanism. 54 61
18495765 2008
30
NADPH oxidase activation is required for migration by LIGHT in human monocytes. 54 61
18468509 2008
31
Uracil-DNA glycosylase (UNG) influences the melting temperature (T(m)) of herpes simplex virus (HSV) hybridization probes. 54 61
18468698 2008
32
Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E. 54 61
18480440 2008
33
High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. 54 61
18287240 2008
34
Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. 54 61
18353920 2008
35
Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. 54 61
18160441 2008
36
The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D. 54 61
18076965 2008
37
Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. 54 61
18193057 2008
38
Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons. 54 61
18066636 2008
39
The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity. 54 61
18949076 2008
40
Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. 54 61
18082566 2007
41
Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. 54 61
18003913 2007
42
Complexes between herpes simplex virus glycoproteins gD, gB, and gH detected in cells by complementation of split enhanced green fluorescent protein. 54 61
17670828 2007
43
Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth. 54 61
17557110 2007
44
Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia. 54 61
17459924 2007
45
Alternative entry receptors for herpes simplex virus and their roles in disease. 54 61
18005714 2007
46
Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector. 54 61
17532884 2007
47
Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. 54 61
17304235 2007
48
Inhibition of cellular 2'-5' oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. 54 61
17229694 2007
49
Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. 54 61
17299053 2007
50
Centromeric protein CENP-B proteasomal degradation induced by the viral protein ICP0. 54 61
17258208 2007

Variations for Herpes Simplex

Expression for Herpes Simplex

LifeMap Discovery
Genes differentially expressed in tissues of Herpes Simplex patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 FCN1 ficolin (collagen/fibrinogen domain containing) 1 Skin + 3.89 0.000
2 IRF1 interferon regulatory factor 1 Skin + 3.58 0.000
3 STAT1 signal transducer and activator of transcription 1, 91kDa Skin + 3.53 0.000
4 RARRES3 retinoic acid receptor responder (tazarotene induced) 3 Skin + 3.49 0.000
5 SERPINB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 Skin + 3.41 0.000
6 CCL19 chemokine (C-C motif) ligand 19 Skin + 3.32 0.003
7 XAF1 XIAP associated factor 1 Skin + 3.04 0.000
Search GEO for disease gene expression data for Herpes Simplex.

Pathways for Herpes Simplex

Pathways related to Herpes Simplex according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
2
Show member pathways
13.21 TRAF3 TNFRSF14 POU2F1 PML IRF3 EIF2AK2
3
Show member pathways
12.94 TRAF3 TLR3 TICAM1 TBK1 IRF3 EIF2AK2
4
Show member pathways
12.86 TRAF3 TLR3 TICAM1 TBK1 IRF3 EIF2AK2
5
Show member pathways
12.7 TRAF3 TLR3 TICAM1 TBK1 TAP2 TAP1
6
Show member pathways
12.65 TRAF3 TLR3 TICAM1 TBK1 IRF3 DDX58
7
Show member pathways
12.56 TRAF3 TLR3 TICAM1 TBK1 TAP2 TAP1
8
Show member pathways
12.53 TRAF3 TBK1 PML EIF2AK2 CREB3
9
Show member pathways
12.37 PML IRF3 EIF2AK2 DDX58
10
Show member pathways
12.29 TLR3 TICAM1 TBK1 IRF3 CREB3
11
Show member pathways
12.26 TLR3 TICAM1 TBK1 IRF3 IFI16 DDX58
12 12.22 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1 TAP2
13 12.15 TRAF3 IRF3 EIF2AK2 CREB3
14
Show member pathways
12.13 TRAF3 TLR3 TICAM1 TBK1 IRF3
15 12.12 TRAF3 TLR3 TICAM1 TBK1 TAP2 TAP1
16 12.09 TRAF3 TICAM1 TBK1 IRF3 IFI16
17 11.84 TICAM1 TBK1 IRF3
18 11.75 TRAF3 TICAM1 DDX58
19
Show member pathways
11.03 IRF3 EIF2AK2 DDX58

GO Terms for Herpes Simplex

Cellular components related to Herpes Simplex according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.8 UNC93B1 TLR3 TAP2 TAP1 POU2F1 PML
2 endoplasmic reticulum membrane GO:0005789 9.63 UNC93B1 TLR3 TAP2 TAP1 PML CREB3
3 apical junction complex GO:0043296 9.32 NECTIN2 NECTIN1
4 MHC class I peptide loading complex GO:0042824 8.96 TAP2 TAP1
5 TAP complex GO:0042825 8.62 TAP2 TAP1

Biological processes related to Herpes Simplex according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 TLR3 TBK1 POU2F1 IRF3 IFI16 DDX58
2 innate immune response GO:0045087 10 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
3 adaptive immune response GO:0002250 9.97 UNC93B1 TNFRSF14 TAP2 TAP1
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.91 TLR3 TICAM1 TBK1 IRF3
5 response to virus GO:0009615 9.84 TLR3 TBK1 EIF2AK2 DDX58
6 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.81 TLR3 TICAM1 TBK1
7 defense response to virus GO:0051607 9.81 UNC93B1 TLR3 TICAM1 TBK1 PML IRF3
8 positive regulation of interleukin-6 production GO:0032755 9.79 TLR3 TICAM1 DDX58
9 positive regulation of type I interferon production GO:0032481 9.77 TLR3 TICAM1 TBK1 IRF3 IFI16
10 immune system process GO:0002376 9.77 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
11 toll-like receptor signaling pathway GO:0002224 9.74 UNC93B1 TRAF3 TLR3
12 negative regulation of type I interferon production GO:0032480 9.73 TBK1 IRF3 DDX58
13 response to exogenous dsRNA GO:0043330 9.73 TLR3 TICAM1 IRF3 DDX58
14 positive regulation of cytokine production GO:0001819 9.72 TLR3 IFI16 EIF2AK2
15 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.72 TRAF3 TLR3 TICAM1 TBK1 IRF3
16 positive regulation of interferon-beta production GO:0032728 9.71 TLR3 TBK1 IRF3 DDX58
17 cellular response to exogenous dsRNA GO:0071360 9.69 TLR3 IRF3 DDX58
18 cellular response to interferon-beta GO:0035458 9.67 TLR3 IFI16
19 necroptotic process GO:0070266 9.67 TLR3 TICAM1
20 toll-like receptor 3 signaling pathway GO:0034138 9.67 UNC93B1 TLR3 TICAM1
21 positive regulation of chemokine production GO:0032722 9.66 TLR3 EIF2AK2
22 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.66 TLR3 TICAM1
23 regulation of protein complex assembly GO:0043254 9.65 TICAM1 HCFC1
24 positive regulation of type I interferon-mediated signaling pathway GO:0060340 9.65 TBK1 IRF3
25 regulation of type I interferon production GO:0032479 9.65 TBK1 IRF3
26 positive regulation of interferon-alpha production GO:0032727 9.65 TBK1 IRF3 DDX58
27 positive regulation of chemokine biosynthetic process GO:0045080 9.64 TLR3 TICAM1
28 peptide transport GO:0015833 9.64 TAP2 TAP1
29 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.63 TAP2 TAP1
30 positive regulation of interferon-beta biosynthetic process GO:0045359 9.63 TLR3 TICAM1 TBK1
31 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.61 TLR3 TICAM1
32 vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane GO:1990668 9.6 TAP2 TAP1
33 detection of virus GO:0009597 9.59 TLR3 DDX58
34 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.58 TICAM1 DDX58
35 virion attachment to host cell GO:0019062 9.58 NECTIN2 NECTIN1
36 cytosol to ER transport GO:0046967 9.52 TAP2 TAP1
37 viral process GO:0016032 9.5 TNFRSF14 TICAM1 TBK1 TAP2 TAP1 PML

Molecular functions related to Herpes Simplex according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.8 TRAF3 TNFRSF14 PML DDX58
2 virus receptor activity GO:0001618 9.63 TNFRSF14 NECTIN2 NECTIN1
3 protein binding GO:0005515 9.62 UNC93B1 TRAF3 TNFRSF14 TLR3 TICAM1 TBK1
4 double-stranded RNA binding GO:0003725 9.58 TLR3 EIF2AK2 DDX58
5 identical protein binding GO:0042802 9.56 TLR3 TBK1 NECTIN2 NECTIN1 IRF3 HCFC1
6 MHC class I protein binding GO:0042288 9.51 TAP1 PILRA
7 MHC protein binding GO:0042287 9.48 TAP2 TAP1
8 peptide transmembrane transporter activity GO:1904680 9.43 TAP2 TAP1
9 MHC class Ib protein binding GO:0023029 9.37 TAP2 TAP1
10 TAP1 binding GO:0046978 9.32 TAP2 TAP1
11 peptide-transporting ATPase activity GO:0015440 9.26 TAP2 TAP1
12 peptide antigen-transporting ATPase activity GO:0015433 9.16 TAP2 TAP1

Sources for Herpes Simplex

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....